Search

Search results

172 results found

Health Maintenance and Preventative Care in Inflammatory Bowel Disease: A Systematic Review of the Overall Quality of Societal Recommendations.

Weissman, Simcha, Hannah K Systrom, Ayrton Bangolo, Daniel Elias, Marcel Awasi, Tamer Zahdeh, Chukwuemeka E Ogbu, et al. 2023. “Health Maintenance and Preventative Care in Inflammatory Bowel Disease: A Systematic Review of the Overall Quality of Societal Recommendations.”. Journal of Clinical Gastroenterology 57 (4): 325-34.

How the integration of normal medical test results can be improved in patients with somatoform disorders-An experimental study.

Kube, Tobias, Jenny Riecke, Jens Heider, Sarah K Ballou, Julia A Glombiewski, Winfried Rief, and Arthur J Barsky. 2023. “How the Integration of Normal Medical Test Results Can Be Improved in Patients With Somatoform Disorders-An Experimental Study.”. Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association 42 (2): 103-12.

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Papamichael, Konstantinos, Adam S Cheifetz, Gil Y Melmed, Peter M Irving, Niels Vande Casteele, Patricia L Kozuch, Laura E Raffals, et al. 2019. “Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.”. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 17 (9): 1655-1668.e3.

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.

Papamichael, Konstantinos, Niels Vande Casteele, Jenny Jeyarajah, Vipul Jairath, Mark T Osterman, and Adam S Cheifetz. 2021. “Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis.”. The American Journal of Gastroenterology 116 (5): 1007-14.

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).

Papamichael, Konstantinos, Vipul Jairath, Guangyong Zou, Benjamin Cohen, Timothy Ritter, Bruce Sands, Corey Siegel, et al. 2022. “Proactive Infliximab Optimisation Using a Pharmacokinetic Dashboard versus Standard of Care in Patients With Crohn’s Disease: Study Protocol for a Randomised, Controlled, Multicentre, Open-Label Study (the OPTIMIZE Trial).”. BMJ Open 12 (4): e057656.